Well, as I expected and predicted in my previous post, the FDA did not waste much time approving ceftaroline (trade name – Teflaro) for complicated skin and skin structure infections (cSSSI). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231594.htm (thanks to Lee Rogers, DPM for forwarding me …
Read more →For a number of years it was widely felt that the first of the new so-called “5th Generation”, or anti-MRSA cephalosporins would be ceftobiprole. This drug, a joint venture by the Swiss company Basilea and Johnson & Johnson had come …
Read more →There is a small group of us that, when we find an interesting article dealing with infections, we pass them on so we can all be stay up to date. Some of the journals are fairly obscure and are not …
Read more →I will be in Columbus, OH for the Region IV (Ohio) meeting to lecture on June 3, 2010. I have been given the “Learning Lunch” spot from 12:00 to 1:30 and plan on covering a broad range of lower extremity …
Read more →I just returned from a lecture trip to Turkey where I had the privilege of giving 5 talks, one in the Mediterranean resort city of Antalya at a nationwide Hospital Infection Congress and 4 to the faculties at various medical …
Read more →Up to this point I have resisted using this blog as a “social networking” tool to just post pictures of myself lecturing someplace or another. It has been my contention that readers of this site are interested in new science …
Read more →(My thanks to David Armstrong, DPM, PhD for bringing this press release to my attention) TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints According to its manufacturer TaiGen, nemonoxacin, a novel, non-fluorinated quinolone has …
Read more →Telavancin (Vibativ – Theravance/Astellas) is a novel lipoglycopeptide, related to vancomycin, that has been recently approved by the FDA for the treatment of complicated skin and skin structure infections (cSSSI) caused by MRSA. Telavancin now joins the ranks of vancomycin, …
Read more →Some interesting news just came out yesterday. It looks like J&J’s new anti-MRSA cephalosporin, ceftobiprole has been, once again, turned back by the FDA. See the story here: http://money.cnn.com/news/newsfeeds/articles/marketwire/0572888.htm Many of us had pretty high hopes for this antibiotic as …
Read more →On Barry Block’s daily PM News (www.podiatrym.com) the other day a colleague presented a case of a neuropathic patient with no wounds presenting with what he felt was osteomyelitis of the 2nd and 3rd metatarsals. Although I did not feel …
Read more →